论文部分内容阅读
[目的]评价低剂量盖诺静脉泵持续点滴治疗晚期转移性乳腺癌的客观疗效及毒副反应。[方法]43例晚期转移性乳腺癌 ,随机分为常规治疗组和持续点滴组。常规治疗组 :盖诺25mg/m2 第1、5天静推 ,DDP30mg/m2 第2～4天静滴。持续点滴组 :盖诺10mg第1天静推 ,盖诺10mg/天静脉泵持续24小时点滴 ,连用5天 ,DDP30mg/m2 第2～4天静滴。4周为1周期 ,化疗2周期。[结果]总有效率持续点滴组61.9%,常规治疗组50.0%,前者有效率虽略高于后者 ,但两组相比较无显著性差异(P>0.05)。血液学毒性是两组主要毒副反应。白细胞下降常规治疗组90.9%,持续点滴组66.7%,两组相比较有显著性差异(P<0.05) ,提示持续点滴较常规治疗血液学毒性明显降低。[结论]盖诺持续点滴治疗晚期转移性乳腺癌近期疗效较高 ,毒性较常规治疗降低
[Objective] To evaluate the objective efficacy and toxicity of low-dose GLENO IV pump in the treatment of advanced metastatic breast cancer. [Methods] 43 cases of advanced metastatic breast cancer were randomly divided into conventional treatment group and continuous drip group. Routine treatment group: Genotol 25mg/m2 intravenous injection on days 1 and 5, DDP 30mg/m2 intravenous infusion on days 2 to 4. The continuous drip-dose group: Gennaro 10 mg intravenously on the first day, Genotau 10 mg/day intravenous pump drip for 24 hours, for 5 days, DDP 30 mg/m2 on the second to fourth days. 4 weeks for 1 cycle, 2 cycles of chemotherapy. [Results] The total effective rate was 61.9% in the continuous drop group and 50.0% in the conventional treatment group. Although the former was slightly more efficient than the latter, there was no significant difference between the two groups (P>0.05). Hematological toxicity is the main toxicity of the two groups. The white blood cells decreased by 90.9% in the conventional treatment group and 66.7% in the continuous drip-dose group. There was a significant difference between the two groups (P<0.05), suggesting that the continuous drip drop was significantly lower than the conventional treatment. [Conclusion] Grenol continued to be effective in the treatment of advanced metastatic breast cancer. The toxicity was lower than conventional therapy.